Back

Drug-drug interactions of empagliflozin and dapagliflozin

30 August 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Drug interactions, efficacy, and safety Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Claudia Stoellberger

Wien (Austria)

7 More presentations in this session

Presentation thumbnail
Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study
Ms A. Lai (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Modulation of p300 acetylation to protect against doxorubicin-induced cardiotoxicity
Mr J. Lee (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Development of a cardiotoxicity evaluation system using a Heart-on-a-Chip Microdevice with aligned fiber device
Doctor K. Murata (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Pregnancy protection in women of child-bearing age prescribed ACE inhibitors, ARBs or statins - A nationwide cohort study
Mr S. Nielsen (Hellerup, DK)
Abstract Slides Video
Presentation thumbnail
Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Drug interactions, efficacy, and safety

The Event

Event poster

ESC Congress 2024

30 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Effects of dapagliflozin on new-onset diabetes in patients with heart failure: a pooled, participant-level analysis of the DAPA-HF and DELIVER trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources